NASDAQ: ANIX |
| Healthcare / Medical Diagnostics & Research / USA |
3.13 | -0.0800 | -2.49% | Vol 48.83K | 1Y Perf -18.73% |
Jun 24th, 2022 16:00 DELAYED |
BID | 3.05 | ASK | 3.30 | ||
Open | 3.25 | Previous Close | 3.21 | ||
Pre-Market | - | After-Market | 3.28 | ||
- - | 0.15 4.79% |
Target Price | 11.00 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 251.44 | Finscreener Ranking | ★★★★★ 60.24 | |
Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★★ 56.31 | |
Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★+ 55.03 | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 23.25 | Earnings Rating | Buy | |
Market Cap | 95.37M | Earnings Date | 9th Jun 2022 | |
Alpha | 0.05 | Standard Deviation | 0.42 | |
Beta | 1.41 |
Today's Price Range 3.083.29 | 52W Range 2.305.87 | 5 Year PE Ratio Range -4.20-7.20 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | 0.64% | ||
1 Month | -11.33% | ||
3 Months | 12.19% | ||
6 Months | -1.57% | ||
1 Year | -18.73% | ||
3 Years | -14.71% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -76.34 | |||
ROE last 12 Months | -48.25 | |||
ROA (5Y Avg) | -19.15 | |||
ROA last 12 Months | -47.23 | |||
ROC (5Y Avg) | -146.09 | |||
ROC last 12 Months | -44.76 | |||
Return on invested Capital Q | -10.64 | |||
Return on invested Capital Y | -11.09 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 12.20 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-6.00 | ||||
2.95 | ||||
192.85 | ||||
18.90 | ||||
-15.70 | ||||
-0.20 | ||||
2.95 | ||||
1.06 | ||||
62.77M | ||||
Forward PE | -5.23 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
27.10 | ||||
27.40 | ||||
0.01 | ||||
0.01 | ||||
- | ||||
Leverage Ratio | 1.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
100.40 | ||||
3.19M | ||||
3.18M | ||||
-2 757.80 | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
-2.49 | ||||
-49.20 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.13 | -0.12 | 7.69 |
Q01 2022 | -0.13 | -0.13 | 0.00 |
Q03 2021 | -0.08 | -0.14 | -75.00 |
Q01 2021 | -0.11 | -0.09 | 18.18 |
Q04 2020 | - | -0.81 | - |
Q03 2020 | -0.12 | -0.11 | 8.33 |
Q02 2020 | - | -0.12 | - |
Q01 2020 | -0.13 | -0.13 | 0.00 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
7/2022 QR | -0.13 | 0.00 | - |
10/2022 QR | -0.13 | 0.00 | - |
10/2022 FY | -0.52 | 0.00 | - |
10/2023 FY | -0.61 | 0.00 | - |
Next Report Date | - |
Estimated EPS Next Report | -0.13 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 48.83K |
Shares Outstanding | 30.47K |
Shares Float | 29.02M |
Trades Count | 363 |
Dollar Volume | 154.40K |
Avg. Volume | 88.57K |
Avg. Weekly Volume | 52.44K |
Avg. Monthly Volume | 124.16K |
Avg. Quarterly Volume | 89.12K |
Anixa Biosciences Inc. (NASDAQ: ANIX) stock closed at 3.13 per share at the end of the most recent trading day (a -2.49% change compared to the prior day closing price) with a volume of 48.83K shares and market capitalization of 95.37M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 4 people. Anixa Biosciences Inc. CEO is Amit Kumar.
The one-year performance of Anixa Biosciences Inc. stock is -18.73%, while year-to-date (YTD) performance is 5.39%. ANIX stock has a five-year performance of %. Its 52-week range is between 2.3 and 5.87, which gives ANIX stock a 52-week price range ratio of 23.25%
Anixa Biosciences Inc. currently has a PE ratio of -6.00, a price-to-book (PB) ratio of 2.95, a price-to-sale (PS) ratio of 192.85, a price to cashflow ratio of 18.90, a PEG ratio of 2.32, a ROA of -47.23%, a ROC of -44.76% and a ROE of -48.25%. The company’s profit margin is -%, its EBITDA margin is 3 176 570.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Anixa Biosciences Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Anixa Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Anixa Biosciences Inc. is Strong Buy (1), with a target price of $11, which is +251.44% compared to the current price. The earnings rating for Anixa Biosciences Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Anixa Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Anixa Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.67, ATR14 : 0.28, CCI20 : -72.77, Chaikin Money Flow : -0.13, MACD : -0.05, Money Flow Index : 45.06, ROC : -9.54, RSI : 44.82, STOCH (14,3) : 12.44, STOCH RSI : 0.18, UO : 46.32, Williams %R : -87.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Anixa Biosciences Inc. in the last 12-months were: Amit Kumar (Buy at a value of $130 340), Arnold Baskies (Buy at a value of $160 270), Emily Gottschalk (Buy at a value of $79 457), Lewis H. Titterton (Buy at a value of $451 607), Michael J. Catelani (Buy at a value of $20 978)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.
CEO: Amit Kumar
Telephone: +1 408 708-9808
Address: 3150 Almaden Expressway, San Jose 95118, CA, US
Number of employees: 4
Thu, 31 Mar 2022 10:25 GMT Analysts Offer Insights on Healthcare Companies: Alaunos Therapeutics (TCRT), Anixa Biosciences (ANIX) and Autolus Therapeutics (AUTL)
- TipRanks. All rights reserved.Wed, 26 Jan 2022 11:25 GMT Analysts Offer Insights on Healthcare Companies: Anixa Biosciences (ANIX) and Roche Holding AG (OtherRHHVF)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.